Korean standardized antimicrobial administration ratio in long-term care hospitals: a benchmark tool
- 1Department of Research, Health Insurance Review & Assessment Service (HIRA)
- 2Division of Infectious Diseases, Department of Internal Medicine, Hanyang University Seoul Hospital
- 3Department of Health Administration, Kongju National University
Abstract
Background Antimicrobial stewardship in long-term care hospitals (LTCHs) is increasingly important; however, standardized benchmarking tools for antimicrobial use in these settings are lacking. The Korean Standardized Antimicrobial Administration Ratio for long-term care hospitals (K-SAAR–LTCHs) was developed to benchmark antimicrobial use in these facilities. Methods We used 2021 National Health Insurance claims data from 1432 LTCHs (387,211 inpatients, including untreated patients) in Korea. Data were split into training (80%) and test (20%) sets at the hospital level for model validation, with 5-fold hospital-level cross-validation within the training set. The main outcome measure was antimicrobial consumption expressed as days of therapy (DOT) per 1000 patient-days. For the fixed-rate cohort, a two-part Hurdle Gamma model addressed zero-inflation; for fee-for-service (FFS) cohorts (pneumonia, septicemia), a Gamma generalized linear model with log link and length of stay as offset was used. Variable selection used stepwise regression with the Akaike Information Criterion (AIC). Predictive performance was evaluated using mean absolute percentage error (MAPE) and calibration metrics (overall observed-to-expected ratio, intercept, slope). The standardized antimicrobial administration ratio (SAAR) was calculated as observed-to-predicted antimicrobial use for each LTCH. For hospital-level benchmarking, 95% funnel plot control limits were calculated using the Byar approximation. Results Antimicrobial use under FFS was substantially higher than under the fixed-rate system (1579.3 vs. 108.3 DOT per 1000 patient-days), reflecting that FFS episodes primarily comprised diagnosis-defined infectious conditions. In the FFS pneumonia and septicemia cohorts, delirium, fever, oxygen therapy, and stage 3 pressure ulcer were consistently associated with higher antimicrobial use, although many rate ratios were modest in magnitude. Hospital-level calibration was strongest for the total-antimicrobial FFS models, whereas broad-spectrum models showed greater between-hospital dispersion. Median hospital-level SAAR values were close to 1.0 in the FFS pneumonia and septicemia cohorts. Funnel plot analysis identified hospitals above the upper control limits in 0.8–1.2% for total antimicrobials, while broad-spectrum antimicrobials showed wider variation, with 4.6–5.7% of hospitals falling below the lower control limits. The fixed-rate hurdle model was developed and evaluated separately, but hospital-level benchmarking was less stable because antimicrobial use was sparse and highly right-skewed. Conclusions The K-SAAR–LTCH framework provides a risk-adjusted approach for monitoring antimicrobial utilization in Korean LTCHs. Hospital-level benchmarking was primarily demonstrated for diagnosis-specific FFS pneumonia and septicemia cohorts, while fixed-rate reimbursement episodes require further refinement before routine benchmarking use. The framework may inform antimicrobial utilization surveillance and targeted stewardship review, but it should not be interpreted as a direct measure of prescribing appropriateness.
Related
- QMAP: a benchmark for standardized evaluation of antimicrobial peptide MIC and hemolytic activity regression
- Nationwide Survey of Antimicrobial Stewardship in Korean Hospitals: Insights From the Early Stage of the 2024 National Pilot Implementation.
- OmniEEG-Bench: A Standardized Evaluation Benchmark for EEG Foundation Models
- Changes in antimicrobial resistance of clinical isolates of Proteus, Morganella, and Providencia species from regional hospitals in Zhejiang Province, 2020 ~ 2024
- eNeuro Assessments: A Standardized Way to Communicate Research Quality
BibTeX
@article{shin2026korean,
title = {{Korean standardized antimicrobial administration ratio in long-term care hospitals: a benchmark tool}},
author = {Jihye Shin and Jungmi Chae and Bongyoung Kim and Dong-Sook Kim},
journal = {Antimicrobial Resistance and Infection Control},
year = {2026},
month = jul,
doi = {10.1186/s13756-026-01795-8},
url = {https://doi.org/10.1186/s13756-026-01795-8},
note = {CC BY},
}
RIS
TY - JOUR
TI - Korean standardized antimicrobial administration ratio in long-term care hospitals: a benchmark tool
AU - Jihye Shin
AU - Jungmi Chae
AU - Bongyoung Kim
AU - Dong-Sook Kim
PY - 2026
DA - 2026/07/01
JO - Antimicrobial Resistance and Infection Control
DO - 10.1186/s13756-026-01795-8
UR - https://doi.org/10.1186/s13756-026-01795-8
AB - Background Antimicrobial stewardship in long-term care hospitals (LTCHs) is increasingly important; however, standardized benchmarking tools for antimicrobial use in these settings are lacking. The Korean Standardized Antimicrobial Administration Ratio for long-term care hospitals (K-SAAR–LTCHs) was developed to benchmark antimicrobial use in these facilities. Methods We used 2021 National Health Insurance claims data from 1432 LTCHs (387,211 inpatients, including untreated patients) in Korea. Data were split into training (80%) and test (20%) sets at the hospital level for model validation, with 5-fold hospital-level cross-validation within the training set. The main outcome measure was antimicrobial consumption expressed as days of therapy (DOT) per 1000 patient-days. For the fixed-rate cohort, a two-part Hurdle Gamma model addressed zero-inflation; for fee-for-service (FFS) cohorts (pneumonia, septicemia), a Gamma generalized linear model with log link and length of stay as offset was used. Variable selection used stepwise regression with the Akaike Information Criterion (AIC). Predictive performance was evaluated using mean absolute percentage error (MAPE) and calibration metrics (overall observed-to-expected ratio, intercept, slope). The standardized antimicrobial administration ratio (SAAR) was calculated as observed-to-predicted antimicrobial use for each LTCH. For hospital-level benchmarking, 95% funnel plot control limits were calculated using the Byar approximation. Results Antimicrobial use under FFS was substantially higher than under the fixed-rate system (1579.3 vs. 108.3 DOT per 1000 patient-days), reflecting that FFS episodes primarily comprised diagnosis-defined infectious conditions. In the FFS pneumonia and septicemia cohorts, delirium, fever, oxygen therapy, and stage 3 pressure ulcer were consistently associated with higher antimicrobial use, although many rate ratios were modest in magnitude. Hospital-level calibration was strongest for the total-antimicrobial FFS models, whereas broad-spectrum models showed greater between-hospital dispersion. Median hospital-level SAAR values were close to 1.0 in the FFS pneumonia and septicemia cohorts. Funnel plot analysis identified hospitals above the upper control limits in 0.8–1.2% for total antimicrobials, while broad-spectrum antimicrobials showed wider variation, with 4.6–5.7% of hospitals falling below the lower control limits. The fixed-rate hurdle model was developed and evaluated separately, but hospital-level benchmarking was less stable because antimicrobial use was sparse and highly right-skewed. Conclusions The K-SAAR–LTCH framework provides a risk-adjusted approach for monitoring antimicrobial utilization in Korean LTCHs. Hospital-level benchmarking was primarily demonstrated for diagnosis-specific FFS pneumonia and septicemia cohorts, while fixed-rate reimbursement episodes require further refinement before routine benchmarking use. The framework may inform antimicrobial utilization surveillance and targeted stewardship review, but it should not be interpreted as a direct measure of prescribing appropriateness.
SN - 2047-2994
ER -